Amicus Therapeutics: Too Cheap At Under $10 A Share [Seeking Alpha]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Seeking Alpha
The company's products, Galafold and Pombiliti + Opfolda, have significant sales potential and are seeing good sales traction. Analyst firms are also largely positive on the company's prospects. An analysis of Amicus Therapeutics is presented in the paragraphs below. Looking for more investing ideas like this one? Get them exclusively at The Biotech Forum. Learn More » Today, we put rare disease concern Amicus Therapeutics ( NASDAQ: FOLD under the spotlight. The shares have recently slid under the $10 a share level, which seems too cheap given the company's revenue growth and movement towards profitability. We dig into recent quarterly results and update our investment analysis on this small-cap name in the paragraphs below. Amicus Therapeutics is headquartered in Princeton, NJ. The company's product portfolio starts with Galafold. This is an oral medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene varian
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the FirmAccesswire
- Investors in Amicus Therapeutics (NASDAQ:FOLD) from a year ago are still down 19%, even after 3.9% gain this past week [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswire
- Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical ProductGlobeNewswire
FOLD
Earnings
- 5/9/24 - Miss
FOLD
Sec Filings
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- FOLD's page on the SEC website